The Anti-Avandia: Phenytoin, Purple Glove Syndrome, and the Eternal Challenge of Drug Safety
This article was originally published in RPM Report
Executive Summary
A look at how FDA handles drug safety when the world isn’t watching. Even without the drama, drug safety issues are never easy.
You may also be interested in...
Vytorin: Yesterday’s News?
Merck’s cholesterol drug is poised to add a unique claim to improve outcomes in as many as 19 million Americans, even though there still isn’t data to answer critics about whether ezetimibe actually adds clinical benefit to conventional statin therapy. Why doesn’t anyone seem to care?
Avandia Revisited: Will New Findings Lead To Reevaluation of Drug Center's Structure?
Senate Finance Committee report and internal FDA analysis on cardiovascular risks associated with GSK's Avandia may revive argument to split CDER into two groups of safety and efficacy reviewers.
Avandia and the Commercial Impact of FDA's Credibility Gap
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.